4//SEC Filing
Kinney Gene G. 4
Accession 0001140361-22-035564
CIK 0001559053other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 9:31 PM ET
Size
23.4 KB
Accession
0001140361-22-035564
Insider Transaction Report
Form 4
Kinney Gene G.
CSO & Head of R&D
Transactions
- Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$58.93/sh−129$7,602→ 12,793 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$48.09/sh−1,045$50,254→ 28,160 total - Exercise/Conversion
Ordinary Shares, par value $0.01 per share
2022-09-28$6.41/sh+16,412$105,201→ 29,205 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$49.41/sh−128$6,324→ 28,032 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$51.30/sh−552$28,318→ 27,480 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$53.40/sh−5,852$312,477→ 19,295 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$55.32/sh−1,342$74,244→ 13,205 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$57.70/sh−243$14,022→ 12,922 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-09-28−16,412→ 0 totalExercise: $6.41Exp: 2023-01-29→ Ordinary Shares (16,412 underlying) - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$52.44/sh−2,333$122,342→ 25,147 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$54.38/sh−4,748$258,177→ 14,547 total - Sale
Ordinary Shares, par value $0.01 per share
2022-09-28$56.19/sh−40$2,248→ 13,165 total
Footnotes (10)
- [F1]The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F10]The Reporting Person holds options that give him the right to acquire an aggregate of 2,004,700 shares at exercise prices ranging from $12.15 to $32.45, of which 1,507,303 are currently exercisable, and 497,397 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award.
- [F2]The transaction was executed in multiple trades in prices ranging from $50.84 to $51.785, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 8 of this Form 4.
- [F3]The transaction was executed in multiple trades in prices ranging from $51.95 to $52.93, inclusive.
- [F4]The transaction was executed in multiple trades in prices ranging from $52.96 to $53.92, inclusive.
- [F5]The transaction was executed in multiple trades in prices ranging from $53.96 to $54.91, inclusive.
- [F6]The transaction was executed in multiple trades in prices ranging from $54.995 to $55.94, inclusive.
- [F7]The transaction was executed in multiple trades in prices ranging from $56.115 to $56.34, inclusive.
- [F8]The transaction was executed in multiple trades in prices ranging from $57.37 to $58.08, inclusive.
- [F9]The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023.
Documents
Issuer
PROTHENA CORP PUBLIC LTD CO
CIK 0001559053
Entity typeother
Related Parties
1- filerCIK 0001564380
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 9:31 PM ET
- Size
- 23.4 KB